LAJIN ENT (08172) announced that on December 4, 2025, the company received a letter from the Hong Kong Stock Exchange (HKEX) outlining the guidance for resuming trading of its shares. According to the resumption requirements, the company must: demonstrate compliance with GEM Listing Rule 17.26; and disclose all material information to the market to enable shareholders and investors to assess its financial condition. The company's shares will remain suspended from trading.